IMPORTANCE Basket-design clinical trials that allow investigation of treatment effects on different clinical syndromes that share the same molecular pathophysiology have not previously been attempted in neurodegenerative disease.OBJECTIVE To assess the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 (abeotaxane) in Alzheimer disease (AD) or the 4-repeat tauopathies (4RT) progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).

Summary This study examined the effect of thymoglobulin induction therapy on leukocyte population dynamics in kidney transplant patients. Patients receiving standard immunosuppression were compared with those who received additional thymoglobulin at the time of kidney transplantation. Thymoglobulin induction led to an immediate and significant decrease of all T cells and NK cells, but not B cells or monocytes. CD8+ T cells recovered to near pretransplant level by 4 weeks post‐transplant. CD4+ T cells remained at less than 30% of pretransplant level for the entire study period of 78 weeks. Both CD4+ and CD8+ T cells showed reduced cytokine production after recovery. Deletion of CD4+FOXP3+HELIOS+ regulatory T cells (Tregs) was less profound than that of CD4+FOXP3− cells, thus the relative percentage of Tregs elevated significantly when compared with pretransplant levels in thymoglobulin‐treated patients. In contrast, the percentages of Tregs and their expression of FOXP3 in the standard immunosuppression group decreased steadily and by 12 weeks after transplant the average percentage of Tregs was 56% of the pretransplant level. Thus, thymoglobulin‐induced deletion of T cells led to significant and long‐lasting alterations of the T‐cell compartment characterized by a preservation of Tregs and long‐lasting reduction in CD4+, and potentially pathogenic, T cells.

A retrospective cohort of 18,453 women with MDD and singleton, non-anomalous gestations was used to examine neonatal outcomes, assessed according to race. Neonatal outcomes included preterm birth (divided into <37, <34 and <32 weeks gestational age), jaundice, neonatal seizures (NS), and respiratory distress syndrome (RDS). Multivariate regression analyses and chisquare tests were employed for statistical comparisons and a p-value of less than 0.05 was used to indicate statistical significance. RESULTS: Overall, race was associated with a statistically significant increase in the majority of investigated outcomes. Compared to neonates of white women, and after controlling for confounders, neonates from black women with MDD were more likely to be delivered preterm before 37 weeks (odds ratio [OR] 1.36; 95% confidence interval [95%CI] 1.15-1.62), 34 weeks (OR 1.28; 95%CI 1.00-1.64), and 32 weeks (OR 1.73; 95%CI 1.29-2.32), and less likely to experience jaundice (OR 0.80; 95%CI 0.67-0.95) Neonates from Hispanic women with MDD were more likely to be delivered preterm at 37 weeks (OR 1.15 ; 95%CI 1.04-1.27), 34 weeks (OR 1.21; 95%CI 1.04-1.39), and 32 weeks (OR 1.48; 95%CI 1.24-1.78), and were less likely to experience RDS (OR 0.75; 95%CI 0.62-0.91). Neonates from Asian/Pacific Islander women with MDD had higher rates of jaundice (OR 1.57; 95%CI 1.35-1.83). CONCLUSION: Neonates of non-white women with MDD experience higher rates of complications than those of white women, with specific complications and rates varying across races. These data may suggest disparities exist in management of pregnant women with MDD across different races.

No abstract